Fusion Antibodies Ltd (FAB) ORD GBP0.04

- Add to watchlist
- Create an alert
- This stock can be held in a




7.25p
9.50p
61.00p
£3.86 million
7.20p
6.25p
3.10p
n/a
3.75p (108.70%) Previous:
3.75p
9,513,442
n/a
5,000
Performance
Not available for this stock.
Fundamental data
Year ending: | 31/03/2023 | 31/03/2022 |
---|---|---|
Revenue (£m) | 2.90 | 4.80 |
Profit before tax (£m) | (2.86) | (1.33) |
Adjusted EPS (p): | (10.00) | (4.60) |
P/E ratio | n/a | n/a |
PEG | n/a | n/a |
EPS growth (%) | n/a | n/a |
Values are quoted in the stock's local currency: British pound
All fundamental dataDividend information for this stock is not available.
Dividend information for this stock is not available.
Ready to invest?
Important Documents
There are no documents available for this stock.
-
Fusion Antibodies appoints interim finance chief
24 August 2023 14:45
-
Fusion Antibodies progresses AI antibody collaboration
21 August 2023 13:43
-
Contract suspensions see Fusion Antibodies warn on revenue
6 March 2023 16:26
-
OptiMAL collaboration agreement
28 November 2023 07:00
-
Half year trading update
9 November 2023 07:00
-
Result of AGM
27 October 2023 11:57
Recent trade data is unavailable. We will be replacing it, however in the meantime the information is available on the London Stock Exchange website.
Annual & interim reports
Annual & interim reports are not available for this stock.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.